Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | QDPR | P09417 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 1/20 | 0.39 |
| ▸ | KHK | P50053 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9934106 | 0.76 | HTR2C (0.47) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL8322515 | 0.76 | HTR2C (0.47) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL5138820 | 0.74 | HTR2C (0.58) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL9310529 | 0.74 | HTR2C (0.58) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| SCHEMBL6816720 | 0.74 | HTR2C (0.43) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Bromide SCHEMBL9325877 | 0.73 | HTR2C (0.56) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6335321 | 0.71 | GSK3A (0.33) | HTR2CHTR2AHTR2BCCNT1CDK9 | |
| Hydrochloric Acid SCHEMBL9934109 | 0.71 | HTR2C (0.49) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL9933989 | 0.71 | HTR2C (0.43) | HTR2CSIGMAR1KDM4EALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL15379330 | 0.70 | HTR2C (0.47) | HTR2CSIGMAR1KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1007523-B9 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2004-09-08 | — | — | EP | disclosed |
| US-6727263-B2 | SEROTONINE REUPTAKE INHIBITOR; ANTIDEPRESSANTS; SIDE EFFECT REDUCTION | H. LUNDBECK A/S (DK) | 2004-04-27 | — | — | US | disclosed |
| EP-1007523-B1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | LUNDBECK & CO AS H (DK) | 2003-10-22 | — | — | EP | disclosed |
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-03-13 | — | — | US | disclosed |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2003-01-23 | — | — | US | disclosed |
| US-6476035-B1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | H. LUNDBECK A/S (DK) | 2002-11-05 | — | — | US | disclosed |
| EP-1246820-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049683-A1 | NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
| EP-1007523-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999005140-A1 | INDOLE AND 2,3-DIHYDROINDOLE DERIVATIVES, THEIR PREPARATION AND USE | H. LUNDBECK A/S (DK) | 1999-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050306-A1 | Novel heteroaryl derivatives, their preparation and use | CRBN, CDR2, DRD3 | HTR2C 18/4885SIGMAR1 349/4885KDM4E 2331/4885 |
| US-20030018050-A1 | Indole and 2,3-dihydroindole derivatives, their preparation and use | TPH1, HTR1A, HTR3A | HTR2C 7/4885SIGMAR1 84/4885KDM4E 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.